Last reviewed · How we verify
Research Insight LLC — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Dexycu intracameral dexamethasone | Dexycu intracameral dexamethasone | marketed | Corticosteroid | Glucocorticoid receptor | Ophthalmology | |
| Cequa | Cequa | marketed | Other | |||
| Lifitegrast 5% Ophthalmic Solution | Lifitegrast 5% Ophthalmic Solution | marketed | LFA-1 antagonist | LFA-1 (lymphocyte function-associated antigen-1) | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 2
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AIDS Malignancy Consortium · 1 shared drug class
- ANI Pharmaceuticals · 1 shared drug class
- AbbVie · 1 shared drug class
- Acrotech Biopharma Inc. · 1 shared drug class
- Allergan · 1 shared drug class
- Aramis Biosciences, Inc. · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Research Insight LLC:
- Research Insight LLC pipeline updates — RSS
- Research Insight LLC pipeline updates — Atom
- Research Insight LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Research Insight LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/research-insight-llc. Accessed 2026-06-10.